Neumora Therapeutics, Inc. (NMRA) - Form 8-K Summary
Business Context and Reporting Period
Neumora Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on May 7, 2026. The filing announces the financial results for the first quarter ended March 31, 2026. The company's common stock trades on The Nasdaq Global Select Market under the symbol NMRA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results have been announced and directs readers to Exhibit 99.1 (Press Release) for the full details.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for specific Q1 2026 financial figures.
- Verify cash position and burn rate details in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the company's status as an emerging growth company and any related accounting election changes.